|
Vitruvia Medical AG / Key word(s): Half Year Results/Half Year Results Vitruvia Medical AG: Half yearly results as per June 30th, 2024 25-Jul-2024 / 21:58 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Vitruvia Medical AG half-year results as of June 30, 2024
Vitruvia Medical AG achieves results as expected in the first half of 2024. The Board of Directors confirms the forecast for the year as a whole. Vitruvia Medical AG is on target for the first six months of 2024. The result amounted to CHF -52,968.06 compared to CHF -150,464.24 in the previous year. Based on the expected results for the first half of 2024, the company’s management confirms the outlook for the current full year. For this period, the Board of Directors expects consolidated sales of around EUR 2.0 million. On a consolidated basis, Vitruvia Medical AG anticipates a further improvement in earnings compared to the previous year. End of Inside Information 25-Jul-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Another Quarter of Weak Revenue Growth for Cannabis Companies
The Public Cannabis Company Revenue & Income Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis companies. This update is our first since
November 15, 2024